Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infection

[1]  K. Kawa,et al.  Epstein-Barr virus--associated diseases in humans. , 2000, International journal of hematology.

[2]  D. Maia,et al.  Chronic, active Epstein-Barr virus infection , 2000, Current opinion in hematology.

[3]  S. Kornblau,et al.  Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. , 1999, Current opinion in oncology.

[4]  W. Zeng,et al.  Successful treatment of Epstein–Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation , 1998, Bone Marrow Transplantation.

[5]  M. Yamori,et al.  Bone marrow transplatation for Epstein-Barr virus-related clonal T cell proliferation associated with hemophagocytosis , 1997, Bone Marrow Transplantation.

[6]  M. Okano.  Therapeutic approaches for severe Epstein-Barr virus infection. , 1997, Pediatric hematology and oncology.

[7]  M. Conley,et al.  Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. , 1996, Bone marrow transplantation.

[8]  K. Ohshima,et al.  Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia , 1996, The Lancet.

[9]  T. Morishima,et al.  Establishment of anti‐Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus‐specific cytotoxic T lymphocytes from an HLA‐matched sibling to a patient with severe chronic active EBV infection , 1996, Clinical and experimental immunology.

[10]  K. Takenaka,et al.  G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. , 1996, Journal of hematotherapy.

[11]  T. Morishima,et al.  Chronic active Epstein‐Barr virus infection in children in Japan , 1995, Acta paediatrica.

[12]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[13]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[14]  A. Lazzarin,et al.  Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system , 1993, The Lancet.

[15]  Masahito Hayashi,et al.  Ganciclovir for chronic active Epstein-Barr virus infection , 1993, The Lancet.

[16]  Y. Sakiyama,et al.  Severe chronic active Epstein-Barr virus infection syndrome , 1991, Clinical Microbiology Reviews.

[17]  P. Pinsky,et al.  A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? , 1987, JAMA.

[18]  A. Tawa,et al.  SUCCESSFUL TREATMENT OF CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION WITH RECOMBINANT INTERLEUKIN-2 , 1987, The Lancet.

[19]  W. Henle,et al.  Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). , 1985, Journal of immunology.

[20]  D. Purtilo,et al.  Chronic Mononucleosis Syndrome , 1984, Southern medical journal.

[21]  E. Ben-Chetrit,et al.  PROLONGED ATYPICAL ILLNESS ASSOCIATED WITH SEROLOGICAL EVIDENCE OF PERSISTENT EPSTEIN-BARR VIRUS INFECTION , 1982, The Lancet.

[22]  M. Kelly.  IMMUNITY AGAINST INFLUENZA. , 1964, Lancet.